MHRA approves gene-editing treatment for children aged 5 and over with serious inherited blood disorders
CRSP•The MHRA approved Casgevy for children aged five and over with severe sickle-cell disease or transfusion-dependent β-thalassemia.
1. Approval expanded to children
The MHRA said children aged five and over with severe sickle-cell disease or transfusion-dependent β-thalassemia can now be treated with Casgevy.
